Literature DB >> 7791100

Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines.

W Erdbrügger1, M Raulf, T Otto, M C Michel.   

Abstract

The authors compared [3H]2-methoxy-idazoxan (RX 821002) and [3H]rauwolscine binding in rat cerebral cortex, spleen and kidney; guinea pig kidney; porcine kidney; human kidney and platelets and HEL and NG 108-15 cells. [3H]RX 821002 had less nonspecific binding and higher affinity than [3H]rauwolscine in most models. Although both ligands detected similar alpha-2 adrenoceptor numbers in rat, porcine and human kidney and in NG 108-15 cells in saturation experiments, [3H]RX 821002 detected more alpha-2 adrenoceptors than [3H]rauwolscine in rat cerebral cortex and spleen, guinea pig kidney, human platelets and HEL cells. These differences were seen in Tris and in glycylglycine buffer regardless of whether EDTA, MgCl2, MgCl2 plus GTP or GTP plus NaCl was added to the former and were not explained by additional labeling of serotonin or dopamine receptors or nonadrenergic sites; in contrast, [3H]rauwolscine also labeled nonadrenergic sites in porcine kidney. In prazosin competition experiments, both ligands differentially recognized alpha-2-adrenoceptor subtypes but this could not account for the observed differences in detected receptor numbers. In epinephrine competition experiments, both ligands labeled similar numbers of agonist low affinity sites in all models; [3H]RX 821002, however, labeled more agonist high-affinity sites than [3H]rauwolscine did in models in which it detected a greater total number of receptors. It was concluded that [3H]RX 821002 is a more suitable ligand for the detection of alpha-2 adrenoceptor than [3H]rauwolscine because of less nonspecific binding, higher affinity and greater specificity for alpha-2 adrenoceptors; moreover, [3H]rauwolscine appears not to detect all agonist high-affinity sites of alpha-2 adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791100

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Dynamics of receptor/G protein coupling in living cells.

Authors:  Peter Hein; Monika Frank; Carsten Hoffmann; Martin J Lohse; Moritz Bünemann
Journal:  EMBO J       Date:  2005-11-17       Impact factor: 11.598

Review 2.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

3.  The effect of alpha 2 adrenoceptor blockers on aggressive behavior in mice: implications for the actions of adrenoceptor agents.

Authors:  J Haller; G B Makara; J L Kovács
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

4.  Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.

Authors:  Inés Artaiz; Arturo Zazpe; Ana Innerárity; Elena Del Olmo; Alvaro Díaz; José Angel Ruiz-Ortega; Elena Castro; Ruth Pena; Luis Labeaga; Angel Pazos; Aurelio Orjales
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes.

Authors:  Martin C Michel; Martina B Michel-Reher; Peter Hein
Journal:  Cells       Date:  2020-08-19       Impact factor: 6.600

6.  The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.

Authors:  Richard G W Proudman; Juliana Akinaga; Jillian G Baker
Journal:  Pharmacol Res Perspect       Date:  2022-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.